Clinical trials: Digestive System
Hepatitis C, Liver Disease
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
This study will explore the relationship of different DEB025 doses in combination with RBV to pharmacokinetic, pharmacodynamic (i.e.
- Trial name
- NCT01970904
- Testing
- Alisporivir, Ribavirin, Peg-IFNα2a
- Where
- 25 sites in Germany, Poland and 2 more
- Volunteers
- 147 people
- Sponsor
- Debiopharm International SA
Metastatic Colorectal Cancer
An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the efficacy of CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) for patients with metastatic colorectal cancer.
- Trial name
- NCT01039506
- Testing
- CPT-11 based regimens
- Where
- Japan
- Volunteers
- 1,376 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Intrahepatic Cholangiocarcinoma (Icc)
An Exosomal miRNA-based Liquid Biopsy for ICC Detection
Intrahepatic cholangiocarcinoma (ICC) is a malignant liver tumor with poor prognosis and limited curative treatment options. Early and accurate detection remains an unmet clinical need.
- Trial name
- LUMIC (NCT07225452)
- Testing
- Small RNA sequencing, LUMIC assay
- Where
- United States
- Volunteers
- 535 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Gastric Cancer (GC), Sentinel Lymph Node Biopsy (SLNB)
Sentinel Lymph Node Detection in Gastric Cancer Using a Dual Tracer (Superparamagnetic Iron Oxide and Methylene Blue): A Prospective Study With Histological and OSNA Validation
Gastric cancer (GC) remains an oncological challenge, where lymph node involvement is a key prognostic factor. Sentinel lymph node (SLN) mapping may improve staging and reduce surgical morbidity.
- Trial name
- SLN_GC_SPIO (NCT07147452)
- Testing
- Dual tracer: The infiltration of the Supermagnetic Iron Oxide (SPIO) and Methylene Blue, OSNA AND H-E
- Where
- Spain
- Volunteers
- 44 people
- Sponsor
- Hospital del SAS de Jerez
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Gastric Cancer
Consistency Between Treatment Responses in PDO Models and Clinical Outcomes in Gastric Cancer
Gastric cancer is the fourth leading cause of cancer-related death worldwide. Accurate assessment of the clinical responses to current treatment regimens is key to improving the prognosis and prolonging the survival of patients.
- Trial name
- NCT05203549
- Testing
- Tumor biopsy
- Where
- China
- Volunteers
- 250 people
- Sponsor
- D1 Medical Technology (Shanghai) Co., Ltd, China
Rectal Cancer, Chemotherapy Effect
Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Preoperative radiation with single agent chemotherapy as sensitizer is the standard care of locally advanced rectal cancer. Local irradiation significantly increases surgical complications and impairs quality of life.
- Trial name
- NCT03975049
- Testing
- Chemoradiation, FOLFOXIRI Protocol, Folfox Protocol
- Volunteers
- 933 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Metastatic Colorectal Cancer
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.
The study is designed to analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with bevacizumab combined with FOLFOX or FOLFIRI regimen in a prospective cohort and to…
- Trial name
- BEV-ONCO2012 (NCT01858649)
- Testing
- Metastases resection, Bevacizumab, 5 FU
- Where
- 11 sites in Belgium
- Volunteers
- 60 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT07435038
- Testing
- BPI-572270
- Where
- 7 sites in Australia, China
- Volunteers
- 120 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Pancreatic Cancer
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.The primary objective is to…
- Trial name
- NCT02278458
- Testing
- icotinib, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Esophageal Cancer, Gastric Cancer
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have esophageal or…
- Trial name
- NCT00003748
- Testing
- irinotecan hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Colorectal Cancer
An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now
The primary objective is to confirm the specificity of a multi-target stool DNA test (mt-sDNA), Cologuard, in an average risk population, ages 45-49.
- Trial name
- NCT03728348
- Testing
- mt-sDNA screening test, Colonoscopy
- Where
- 39 sites in United States
- Volunteers
- 983 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Hepatic Steatosis, NAFLD
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
Participants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo "fake supplement" for 2 months to see if the participants who get the protein supplement have less…
- Conditions
- Hepatic Steatosis, NAFLD, Adolescent Obesity
- Trial name
- AMINOS (NCT05935826)
- Testing
- Essential Amino Acid Supplement by Amino Co
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Colorado, Denver
Pancreas Adenocarcinoma, Pancreas Metastases
Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX
This is a prospective, pilot study from a single center. Patients will be evaluated and operated on by one of five surgeons with a subspeciality in hepato-biliary and pancreatic surgery.
- Conditions
- Pancreas Adenocarcinoma, Pancreas Metastases, Pancreas Cancer
- Trial name
- PDAC-LIV (NCT06349278)
- Testing
- Pancreatic resection and non-anatomic liver resections.
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Laval University
Hepatitis C
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
The purpose of this study is to determine whether a regimen consisting of daclatasvir and asunaprevir is effective in treatment-naive patients with chronic hepatitis genotype 1b infection.
- Trial name
- NCT02496078
- Testing
- Daclatasvir, Asunaprevir
- Where
- 29 sites in China, Russia and 1 more
- Volunteers
- 207 people
- Sponsor
- Bristol-Myers Squibb
Crohn's Disease, Ulcerative Colitis
Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease
An increase prevalence of CMV, EBV and or HHV-6 in diseased tissue of inflammatory bowel disease would suggest a role for these viruses in the etiology and/or exacerbation of IBD, whereas their absence would preclude such…
- Trial name
- NCT00222378
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- University of Miami
Colorectal Polyp, Colorectal Neoplasms
Underwater Versus Conventional Endoscopic Mucosal Resection in the Treatment of Non-pedunculated Colorectal Polyps
A prospective, randomized, controlled study to compare the efficacy and safety of underwater endoscopic mucosal resection and conventional endoscopic mucosal resection in removal of non-pedunculated colorectal polyps
- Trial name
- NCT05825664
- Testing
- Endoscopic resection
- Where
- Vietnam
- Volunteers
- 228 people
- Sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
PMS, Menstrual Cramp
A Randomized Placebo-Controlled Study to Evaluate the Effects of a Gummy and Capsule Supplement on Symptoms of Premenstrual Syndrome
This virtual, randomized, placebo-controlled clinical trial evaluates the effectiveness of a PMS capsule and PMS gummy in alleviating premenstrual syndrome symptoms over 12 weeks.
- Conditions
- PMS, Menstrual Cramp, Mood Change
- Trial name
- NCT06763809
- Testing
- PMS Capsule, PMS Gummy
- Where
- United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Semaine Health
Anal Cancer
Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma
This phase 2 single-arm study will evaluate whether a shortened course of mildly hypofractionated radiation therapy given with standard concurrent chemotherapy (mitomycin C and capecitabine) can provide acceptable tumor control…
- Trial name
- SSIBLING (NCT07775209)
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Vermont Medical Center
Lung Cancer, Colorectal Cancer
Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)
Over-expression of Epidermal Growth Factor Receptor (EGFR) on cells occurs in all aggressive cancers of epithelial origin. Existing tests for monitoring EGFR expression are invasive and not reliable.
- Trial name
- NCT04235114
- Testing
- 50 mg 89Zr-DFO-Nimotuzumab, 1 mg 89Zr-DFO-Nimotuzumab
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University of Saskatchewan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.